FDA approves use of Lynparza for pancreatic cancer
SILVER SPRING, Md. — Pancreatic cancer patients will now have a new treatment option. The Food and Drug Administration has approved the use of AstraZeneca’s Lynparza for patients with tumors that didn’t grow after 16 weeks of chemotherapy. The drug is currently used to treat ovarian and breast cancer. Pancreatic cancer is the third largest cause
